A recent study published in Pharmacological Reports aimed to compare the effects of two therapies of equal hipolipemic efficacy on the erythrocyte membrane fluidity, concentration of membrane cholesterol, lipids peroxidation and RBCs distribution in patients with cardiovascular diseases (CVD). This study enrolled 44 patients with angiographic evidence of CVD, who did not achieve the low-density lipoprotein cholesterol (LDL-C) concentration <70 mg/dl after a 6-month hypolipemic therapy. These patients were randomly assigned to rosuvastatin 20 mg/day (R20) and atorvastatin 10 mg/day combined with ezetimibe 10 mg/day (A10 + E10). It was observed that each of the groups studied exhibited improvement in lipid parameters. In addition, the R20 group displayed 33% reduction in concentrations of thiobarbituric acid reactive substances (TBARS) in serum, as well as in a decrease in membrane cholesterol by 16%; fluorescence anisotropy of trimethylammonium-diphenylhexatriene (TMA-DPH) by 17.7%; and fluorescence anisotropy of DPH by 2.8%. While in the A10 + E10 group, reduction of TBARS by 20.5% in serum; membrane cholesterol by 15.8%; a 14.25% increase in RBC membrane fluidity in the superficial layer (TMA-DPH); and decrease fluidity in the deep layer (DPH) were noted. Thus, it was concluded that rosuvastatin increases the fluidity of erythrocyte membrane and decreases the TBARS in serum to greater extent than does equal hipolipemic combined therapy atorvastatin with ezetimibe.